Clinical trial
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
NCT00479089 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00479089 |
|---|---|
| Title | Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer |
| Official title | Phase II Trial of Weekly Docetaxel (Taxotere) Vs. Weekly Docetaxel in Combination With ZD1839 (Iressa®) As Consolidation Therapy For Metastatic Urothelial Cancer Following Maximal Response To Multi-Agent Chemotherapy |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | AstraZeneca Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, ZD1839, Dexamethasone |
| Enrollment | 50 |
| Start date | Feb 1, 2004 |
| Primary completion | Aug 1, 2014 |
| Completion | Aug 1, 2014 |
| First posted | May 25, 2007 |
| Last update posted | Nov 2, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: